Antibody-drug conjugates are inherently heterogeneous. Attributes like DAR, aggregation, charge variants, glycosylation, and free payload levels directly influence safety, efficacy, pharmacokinetics, and comparability. Robust, phase-appropriate characterization enables stability testing, monitors product consistency, supports comparability assessments, generates validation- and GMP-ready data, and builds confidence for regulatory submissions and lifecycle management.